Five FDA enforcement records list Mindray DS USA, Inc. as the recalling firm, each classified Class III and each tied to operator's manuals rather than to a device hardware change. The records share an event identifier, a recall initiation date of August 31, 2026, and a center classification date of October 7, 2026, with report dates of October 14, 2026. All five are marked ongoing and voluntary, firm initiated, with letters as the initial notification. Distribution is described as worldwide, nationwide and the country of Canada. The affected products span bedside and telemetry monitoring lines, and the stated reason in each record concerns manual descriptions of selected physiological alarm functions. [1][2][3][4][5]

What the five records cover

The BeneVision N1 and N-Series record covers N12, N15, N17, N19 and N22 monitors and lists 44,651 units, citing operator's manuals up to revision 21.0 for the N1 and up to revision 23 for the N-Series. The ePM Series record covers ePM 10M, ePM 12M, ePM 12MA, ePM 15M and ePM 10A and lists 32,184 units, with manual part numbers including a Guardian Plus OEM manual. The Panorama and Telemetry Monitoring System record covers TMS-6016, Panorama Telepack-608 and TMS60 (TD60) and lists 11,831 units. The cPM Series record covers cPM 8 and cPM 12 and lists 1,699 units. The BeneVision Series Telemetry record covers TM70 and TM80 and lists 29,737 units. [1][2][3][4][5]

Each record identifies the affected manuals by part number and revision ceiling, so the scope is documentary: for example, the cPM 12/cPM 8 manual up to revision 4.0 under part 046-011732-00, and the TM70 manual up to revision 4.0 under part 046-019362-00. The records do not describe a field correction to monitor hardware or software, and they do not state which manual passages are affected beyond the general reference to selected physiological alarm functions. [4][5]

Product identity and published documentation

Mindray's own BeneVision N-Series Monitor and Module Guide describes the N-Series as a modular continuous patient monitoring platform, with the N1 as a multi-parameter module and transport monitor with a 5.5-inch touchscreen and parameter options including ECG, SpO2, respiration, invasive blood pressures, temperature, NIBP, integrated CO2 and 12-lead ECG. The same guide lists 12-, 15- and 18.5-inch bedside monitors with integrated module slots. [8]

A BeneVision N22/N19/N17/N15/N12 Patient Monitor Operator's Manual published by Shenzhen Mindray Bio-Medical Electronics Co., Ltd. carries a March 2026 release date and revision 8.0, and includes a U.S. federal law statement restricting sale to or on the order of a physician or other licensed practitioner. An FDA establishment registration and device listing entry names the BeneVision N Series, N1, N12, N15, N17 and N19 patient monitors. [9][10]

How to read the collection

The linked-record count for this company is zero, and the five enforcement records above are the documented filing set in this snapshot. Unit quantities in those records describe the products tied to each recall, not company sales or total installed base, and the Class III designation is the FDA classification recorded for these entries. The records do not state a root cause beyond manual wording, a corrective action beyond the notification letter, or a completion date. [1][2][3][4][5]

The FDA recall database pages for the BeneVision N1 and N-Series entry reproduce the Class 3 Device Recall heading but the retrieved page text contains navigation and agency boilerplate rather than additional product detail, so the enforcement record remains the substantive description of that action. [6][7]